国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (6): 472-475.

• 综述 • 上一篇    下一篇

PCI-32765在治疗B细胞恶性肿瘤中的应用

屈福莲, 夏冰, 张翼鷟   

  1. 300060 天津医科大学附属肿瘤医院肿瘤防治重点实验室
  • 出版日期:2013-06-08 发布日期:2013-05-24
  • 通讯作者: 张翼鷟，E-mail:aprilzyz@yahoo.com E-mail:aprilzyz@yahoo.com

Clinical application of PCI-32765 for the treatment of B cell malignancies

QU  Fu-Lian, XIA  Bing, ZHANG  Yi-Zhuo   

  1. Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

  • Online:2013-06-08 Published:2013-05-24
  • Contact: ZHANG Yi-zhuo E-mail:aprilzyz@yahoo.com

PDF

1752

摘要： PCI-32765是一种口服的Bruton酪氨酸激酶（BTK）抑制剂，可通过选择性、不可逆地抑制BTK，阻断B细胞受体信号通路，抑制B细胞的生存、活化、增殖和迁移。PCI-32765不仅能直接作用于恶性肿瘤B细胞，还能防止肿瘤细胞产生耐药性。因此，PCI-32765在B细胞恶性肿瘤的治疗中具有广阔的应用前景。

关键词: 淋巴瘤, 药物疗法, 信号转导

Abstract: PCI-32765, an oral selective and irreversible inhibitor of Bruton tyrosine kinase (BTK), inhibits survival, activation, proliferation and migration of malignant B cells by blocking B cell receptor signaling pathway. PCI-32765 not only acts on malignant B cell, but also prevents resistance to chemical drugs. Therefore, PCI-32765 has broad prospects in the treatment of B cell malignancies.

Key words: Lymphoma, Drug therapy, Signal transducing